Institute of Virology, Technische Universität München, Munich, Germany.
Dig Dis. 2013;31(1):138-51. doi: 10.1159/000347209. Epub 2013 Jun 17.
Hepatocellular carcinoma (HCC) ranks as the third leading cause of cancer-related death worldwide with currently limited treatment options. Chronic hepatitis B virus (HBV) infection accounts for HCC development in more than 50% of cases. The lifetime risk of HBV carriers to develop cirrhosis, liver failure or HCC is estimated to be as high as 15-40%. Although several pathways and triggers contributing to HCC development have been described, many features of hepatocellular carcinogenesis and the attributed direct role of viral factors remain elusive. Host genetic factors, the geographic area and epidemiologic factors, as well as the direct risk related to chronic HBV and hepatitis C virus (HCV) infections, account for geographical and gender differences of HCC prevalence. There is growing evidence that hepatocarcinogenesis is a multistep process. Human HCC is typically preceded by chronic inflammation and apoptotic and nonapoptotic cell death with compensatory liver proliferation. However, we still lack a thorough understanding of the common underlying molecular mechanisms. High levels of HBV replication and chronicity of inflammation are known to independently increase the risk for HCC. A direct carcinogenic role of viral factors is very likely to contribute to liver cancer since HCC is known to also occur in noncirrhotic livers of individuals with an inactive chronic or even with occult HBV infection with no significant histological signs of inflammation or cytopathic effects. Furthermore, synergistic or independent viral risk factors for primary liver cancer development have been described, such as HBV genotype, integration of viral DNA into the host genome and direct effects of viral proteins. A broader understanding of these viral factors in hepatocarcinogenesis might give rise to new diagnostic and therapeutic means in the future. We review the current state of research in liver cancer development and focus on the role of direct viral factors in HBV infection.
肝细胞癌 (HCC) 是全球第三大癌症相关死亡原因,目前治疗选择有限。慢性乙型肝炎病毒 (HBV) 感染占 HCC 发病的 50%以上。HBV 携带者发展为肝硬化、肝功能衰竭或 HCC 的终生风险估计高达 15-40%。尽管已经描述了导致 HCC 发展的多个途径和触发因素,但肝细胞癌发生的许多特征以及病毒因素的直接作用仍不清楚。宿主遗传因素、地理区域和流行病学因素以及与慢性 HBV 和丙型肝炎病毒 (HCV) 感染相关的直接风险,导致 HCC 流行的地理和性别差异。越来越多的证据表明,肝癌发生是一个多步骤的过程。人类 HCC 通常以前有慢性炎症、凋亡和非凋亡细胞死亡,伴有代偿性肝增殖。然而,我们仍然缺乏对常见潜在分子机制的全面了解。高水平的 HBV 复制和炎症的慢性是已知独立增加 HCC 的风险。病毒因素的直接致癌作用很可能导致肝癌,因为 HCC 也发生在非肝硬化的个体中,这些个体的慢性 HBV 感染处于不活跃状态,甚至隐匿性感染,没有明显的炎症或细胞病变作用的组织学迹象。此外,还描述了原发性肝癌发展的协同或独立的病毒危险因素,如 HBV 基因型、病毒 DNA 整合到宿主基因组中和病毒蛋白的直接作用。对这些病毒因素在肝癌发生中的作用有更广泛的了解,可能会为未来带来新的诊断和治疗手段。我们综述了肝癌发展的研究现状,并重点介绍了直接病毒因素在 HBV 感染中的作用。